More about our sector?

this is your place

2019 Xavier University AI Summit Reflections – Two Industries Ready for Change

2019 Xavier University AI Summit Reflections – Two Industries Ready for Change

 

Now that the dust has settled from the Xavier University AI Summit and our team is back to business, we’ve had time to process some of the highlights and key takeaways from the exciting event.  In the past few years, there has been a significant increase in the implementation of digital technologies into various industries that subsequently impacted the way we live, travel, and do business.  From driverless cars to 24/7 customer support chatbots, innovation and technology continue to spiral upward and as we’ve entered the 4th industrial revolution, and healthcare + biopharma should be no exception.  The Xavier University AI Summit is a great event that brings together a range of relevant stakeholders with common focus on artificial intelligence (AI). Together we address the challenges of AI, share initiatives and success stories, and ultimately get a pulse check on where the pharmaceutical and medical device industries are regarding the use of AI.  

 

  • As a first take, this year’s attendee list included the expected top healthcare companies in addition to leading technology companies, like AWS.  The engagement of these tech companies coming from outside of the healthcare industry is a true testament to the major paradigm shift the industry is going through nowadays.  From FDA presentations on the exploration of the power of AI to fireside chats on discovery and innovation, there was an underlying message throughout the summit – the industry needs the pharma 4.0 technologies.  To those who may not have a clear understanding of what we mean by pharma 4.0, check out our blog post where we bring more color to the new wave of disruptive technologies.  

 

  • Secondly, this summit’s focus was on AI and the benefits it can bring to an industry that is known to lack in innovative technologies due to strong regulation. The message was clear – it is almost irresponsible not to pursue the advantages offered by AI, to help deserving patients get better treatments and therapies.  AI is the combination of statistics, software, and computation to provide predictions, recommendations, classifications and patterns in a similar way than humans do. The benefits of AI are new and novel, from improving drug discovery to manufacturing drugs faster to reducing drug development costs.  On average, 9/10 clinical drugs fail to make it trail costing companies around $1.2 billion to develop new drugs. Adoption to AI can elevate pressures from pharma companies, decreasing the amount of money spent on creating drugs and bringing them to market sooner.  There are countless benefits that other industries have experienced using digital technologies like AI and now it is time to establish the right procedures for our industry.  

 

  • Lastly, there was a clear joined effort between pharmaceutical and medical device industries to establish a roadmap on how to implement AI into the health sector.  FDA regulators at the event also provided their strong support to achieve AI implementation to bring the power of AI to the benefit of patients. As we’ve shared previously, the FDA has continued to work towards understanding new digital technologies creating programs like the ETT program.  AI benefits are expanding in various other sectors with industry leaders of tomorrow adapting and embracing new technology which has proven to be as beneficial inside our society today. The path to apply the same outcome in pharmaceutical and the medical device industry only requires to include the same science applied to the processes and products that are being carried in companies today. 

 

As we look to the future of the pharmaceutical and medical device, the power of AI will shape the future of our industry.  Thanks in no small part to the initiatives from the AI Xavier Health University!

Melissa Villalobos

Sales and Marketing Coordinator

2019 Xavier University AI Summit Reflections – Two Industries Ready for Change

Now that the dust has settled from the Xavier University AI Summit and our team is back to business, we’ve had time to process some of the highlights and key takeaways from the exciting event.  In the past few years, there has been a significant increase in the implementation of digital technologies into various industries that subsequently impacted the way we live, travel, and do business.  From driverless cars to 24/7 customer support chatbots, innovation and technology continue to spiral upward and as we’ve entered the 4th industrial revolution, and healthcare + biopharma should be no exception.  The Xavier University AI Summit is a great event that brings together a range of relevant stakeholders with common focus on artificial intelligence (AI).

Bigfinite and NNE Partnership

Bigfinite and NNE announced a strategic partner program agreement to collaborate around accelerating digital transformation within manufacturing operations at the world's leading pharmaceutical and biotech manufacturers. 

Where are Pharma Companies in the Age of Artificial Intelligence?

They say good things come to those who wait; we say good things come to those who wait but only the things left by the visionaries before them.  The pharmaceutical industry has long been known to lag in the adoption of new technology due to strong regulations. Even though regulators have recently begun to open up to several new ‘big data’ or pharma 4.0 technologies - the question remains, if pharma companies are doing the same?  In 2016, the European Pharmacopoeia 9.0 in Chapter 5.21 announced that neural networks (NN) and support vector machines (SVM) are valid chemometric techniques for processing analytical data sets. 

Data Scientist 4.0 – Bridging the World of Manufacturing and Data

Since the announcement of the 4th Industrial Revolution in 2011, multitudes of emerging technologies have transpired around “Industry 4.0”. Technologies such as digital twins, Industrial Internet of Things (IIoT), and cyber-physical systems have come into the scene as core elements, providing the necessary ingredients for a paradigm shift in manufacturing. Technologies around predictive analytics and artificial intelligence are pioneering new approaches with many use cases including predictive maintenance, autonomous process optimization, and pattern recognition - used to identify potential failures in real-time. Because of this, data science is becoming an invaluable discipline for our industry in order to transform information into knowledge.

Making the Conversation Real – What To Expect From The AI Manufacturing Team At Xavier University

Our co-founder and R&D Director Toni Manzano is a team lead for Xavier University AI in Manufacturing Team where, with the help of FDA officials and industry professionals, they address how the power of AI can be used to optimize manufacturing operations in the life sciences industry.

Taking Smart Manufacturing “Back to The Future”

What does the future look like in a smart factory in the pharma or biotech industry? We believe a smart factory is a digitally transformed facility and operation that is reaping the benefits of increased productivity. In fact, some experts predict an order of magnitude productivity gain! It is this productivity gain we need to aim and think about when talking digital transformation, it is the vision and the clear long-term goal. And yes, it is super important because with a clear goal it is easier to prioritize which technology to try first and where or what to digitally transform first, in other words, the strategy.

AWS re:Invent 2018 is Here!  Are You Ready?

Bigfinite is excited to announce that we will be attending the 2018 AWS re:Invent!  For the past three years, we have attended the annual conference and every year this event has continued to gain tremendous growth and take the city by storm.

Cultural Resistance… Who are the Real Enablers?

Advanced analytics technologies in the pharmaceutical industry are accessible now more than ever and regulators have slowly become more accepting of these kinds of advances.  The introduction of machine learning, artificial intelligence, and big data technologies are disrupting our industry, and it’s time we change our mindset.

Gartner Selects Bigfinite as “2018 Cool Vendor for Life Sciences”

We are excited to share that Bigfinite was selected as a 2018 Gartner Cool Vendor for Life Sciences - the only company solely focused on GxP manufacturing intelligence and analytics!

A story about adoption – Pharma 4.0 at the world’s largest insulin manufacturers

Pharma 4.0 is a popular topic in this years ISPE Annual Meeting event in Philly and currently of great interest in the industry as a whole.